BR0008631A - Glicina betaìna para uso antitrombótico - Google Patents

Glicina betaìna para uso antitrombótico

Info

Publication number
BR0008631A
BR0008631A BR0008631-2A BR0008631A BR0008631A BR 0008631 A BR0008631 A BR 0008631A BR 0008631 A BR0008631 A BR 0008631A BR 0008631 A BR0008631 A BR 0008631A
Authority
BR
Brazil
Prior art keywords
betaine
glycine
relates
glycine betaine
thrombi
Prior art date
Application number
BR0008631-2A
Other languages
English (en)
Inventor
Jallal Messadek
Original Assignee
Jallal Messadek
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Jallal Messadek filed Critical Jallal Messadek
Publication of BR0008631A publication Critical patent/BR0008631A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/205—Amine addition salts of organic acids; Inner quaternary ammonium salts, e.g. betaine, carnitine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Materials For Medical Uses (AREA)
  • Medicinal Preparation (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Compounds Of Unknown Constitution (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

Patente de Invenção: "GLICINA BETAìNA PARA USO ANTITROMBóTICO". Esta invenção refere-se ao uso de glicina betaína para eliminar ataques vasculares fisiopatológicos. A invenção refere-se à atividade curativa e preventiva de glicina betaína na patogênese de doenças tromboembólicas e hemostáticas de origem arterial ou venosa. Glicina betaína apresenta uma atividade de prevenção ao inibir a formação de trombos e uma atividade curativa que inibe a proliferação de trombos ao eliminá-los. A invenção caracteriza-se pelo fato de que glicina betaína não apresenta qualquer risco de hemorragia ou alergia contrariamente a moléculas e tratamentos presentemente utilizados. A invenção também refere-se ao uso de glicina betaína como anticoagulante para conservação de sangue.
BR0008631-2A 1999-03-02 2000-03-01 Glicina betaìna para uso antitrombótico BR0008631A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
BE9900144A BE1012495A3 (fr) 1999-03-02 1999-03-02 La glycine-betaine pour son usage antithrombotique.
PCT/BE2000/000021 WO2000051596A1 (fr) 1999-03-02 2000-03-01 La glycine betaïne pour son usage antithrombotique

Publications (1)

Publication Number Publication Date
BR0008631A true BR0008631A (pt) 2002-02-13

Family

ID=3891794

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0008631-2A BR0008631A (pt) 1999-03-02 2000-03-01 Glicina betaìna para uso antitrombótico

Country Status (20)

Country Link
US (1) US6855734B2 (pt)
EP (1) EP1156796B1 (pt)
JP (1) JP2002538113A (pt)
KR (1) KR100767270B1 (pt)
CN (1) CN1194681C (pt)
AT (1) ATE311226T1 (pt)
AU (1) AU2897900A (pt)
BE (1) BE1012495A3 (pt)
BR (1) BR0008631A (pt)
CA (1) CA2362558C (pt)
DE (1) DE60024415T2 (pt)
EA (1) EA004047B1 (pt)
ES (1) ES2254144T3 (pt)
HK (1) HK1044276B (pt)
HU (1) HUP0105397A3 (pt)
IL (1) IL145068A0 (pt)
MX (1) MXPA01008426A (pt)
NZ (1) NZ513905A (pt)
PL (1) PL204560B1 (pt)
WO (1) WO2000051596A1 (pt)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUP9900213A1 (hu) * 1999-02-01 2000-12-28 Gábor Bogye Gyógykompozíció(k) gesztagén tipusú hormon tartalmú gyógyszerek thromb-embóliás mellékhatásainak mérséklésére
US7608640B2 (en) 1999-03-02 2009-10-27 Jallal Messadek Glycine betaine and its use
CA2441948A1 (en) * 2001-02-05 2002-08-15 Jallal Messadek Glycine betaine and its use as anti-hemorrhagic agent
BE1015608A6 (fr) 2003-07-15 2005-06-07 Messadek Jallal Traitement des arterites.
US20060160896A1 (en) * 2002-02-04 2006-07-20 Jallal Messadek Therapeutic treatment
US7759506B2 (en) 2002-02-25 2010-07-20 Diffusion Pharmaceuticals Llc Bipolar trans carotenoid salts and their uses
CA2477245A1 (en) * 2002-02-25 2003-09-04 Diffusion Pharmaceuticals Llc Bipolar trans carotenoid salts and their uses
EP1569692B1 (en) * 2002-11-25 2010-11-10 Jallal Messadek Betaine and salicylic acid compositions
US8697679B2 (en) 2003-03-07 2014-04-15 N.V. Nutricia Method and composition for treating or preventing catabolism or stimulating anabolism in a mammal undergoing metabolic stress
ES2278314T3 (es) * 2003-04-17 2007-08-01 Jallal Messadek Formulaciones orales para la liberacion controlada de la betaina.
CA2575760A1 (en) * 2003-08-04 2005-02-10 Jallal Messadek Selected betaines and their uses
BE1016128A6 (fr) * 2004-07-22 2006-03-07 Messadek Jallal Combinaisons therapeutiques
WO2006050581A2 (en) * 2004-11-10 2006-05-18 Jallal Messadek Betaine as agent against arthropod - or mosquito -borne diseases
WO2006086856A1 (en) 2005-02-15 2006-08-24 Messadek, Jallal Combination therapeutic compositions and method of use
EP2540696B1 (en) 2005-02-24 2020-01-01 Diffusion Pharmaceuticals LLC Trans carotenoids, formulation and uses
ATE540690T1 (de) 2005-04-27 2012-01-15 Jallal Messadek Insulinkombinationen
US9597311B2 (en) * 2005-09-27 2017-03-21 Robert Benson Aylor Suppression and prevention of tumors
US8557863B2 (en) * 2005-09-27 2013-10-15 Robert Benson Aylor Suppression and prevention of tumors
CN101687757A (zh) 2007-04-13 2010-03-31 扩散药品有限公司 双极性反式类胡萝卜素作为预治疗及其在周围血管疾病的治疗中的应用
KR20100083820A (ko) * 2007-10-31 2010-07-22 디퓨젼 파마슈티컬즈 엘엘씨 저분자 확산을 촉진시키는 신규한 치료요법
WO2009065193A1 (en) * 2007-11-21 2009-05-28 Jallal Messadek Treatment of aspirin resistance with betaine and/or betaine enriched molasses
EP2445339B1 (en) 2009-06-22 2019-08-07 Diffusion Pharmaceuticals LLC Diffusion enhancing compound and its use with a thrombolytic
AU2011262361A1 (en) 2010-06-02 2013-01-10 Diffusion Pharmaceuticals Llc Oral formulations of bipolar trans carotenoids
CA3018550A1 (en) 2016-03-24 2017-09-28 Diffusion Pharmaceuticals Llc Use of bipolar trans carotenoids with chemotherapy and radiotherapy for treatment of cancer
CN109342606B (zh) * 2018-12-05 2021-11-02 宁波市产品食品质量检验研究院(宁波市纤维检验所) 一种水产品中甘氨酸甜菜碱的检测方法
US11285349B1 (en) * 2019-10-07 2022-03-29 TFS Holdings, LLC Sprinkler system antifreeze compositions and methods
CN111505131B (zh) * 2020-01-02 2023-03-31 东莞东华医院有限公司 基于血清代谢组学改变建立的预测冠心病斑块不稳定性临床模型

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4980277A (en) * 1987-10-16 1990-12-25 Cultor Ltd. Cryoprotectant solution and method
HU210122B (en) 1988-03-23 1995-02-28 Biorex Kutato Fejlesztoe Kft Process for production of composition against thromboembolytic conditions of circulating system and heart
EP0347864A3 (en) * 1988-06-24 1992-04-01 Andries Johannes Cornelus Strydom Anti-atherogenic agents
WO1995015750A1 (en) * 1993-12-10 1995-06-15 Hashim Sami A Reducing likelihood of vascular disorders in susceptible patients
JP3119430B2 (ja) * 1995-07-25 2000-12-18 大鵬薬品工業株式会社 水酸基ラジカル消去剤
LV11727B (en) * 1995-08-21 1997-08-20 Kalvins Ivars Pharmaceutical composition
US5880098A (en) * 1996-04-12 1999-03-09 Pharmacia & Upjohn Aktiebolag Therapeutic treatment
SE9601396D0 (sv) * 1996-04-12 1996-04-12 Dieter Haeussinger New therapeutic treatment 2
US6008221A (en) * 1996-11-06 1999-12-28 Bristol-Myers Squibb Company Method for treating Alzheimer's disease with folic acid
US6162852A (en) 1996-12-13 2000-12-19 Isolyser Company, Inc. Degradable polymers

Also Published As

Publication number Publication date
DE60024415D1 (de) 2006-01-05
CN1194681C (zh) 2005-03-30
CA2362558C (fr) 2009-06-02
HK1044276A1 (en) 2002-10-18
EP1156796A1 (fr) 2001-11-28
ATE311226T1 (de) 2005-12-15
IL145068A0 (en) 2002-06-30
ES2254144T3 (es) 2006-06-16
HK1044276B (zh) 2006-12-22
NZ513905A (en) 2001-09-28
WO2000051596A9 (fr) 2001-10-11
PL350408A1 (en) 2002-12-02
HUP0105397A2 (hu) 2002-05-29
BE1012495A3 (fr) 2000-11-07
CN1342071A (zh) 2002-03-27
AU2897900A (en) 2000-09-21
CA2362558A1 (fr) 2000-09-08
KR100767270B1 (ko) 2007-10-17
DE60024415T2 (de) 2006-09-21
HUP0105397A3 (en) 2003-03-28
WO2000051596A1 (fr) 2000-09-08
PL204560B1 (pl) 2010-01-29
JP2002538113A (ja) 2002-11-12
EA200100925A1 (ru) 2002-04-25
KR20020021369A (ko) 2002-03-20
MXPA01008426A (es) 2003-06-06
US6855734B2 (en) 2005-02-15
EP1156796B1 (fr) 2005-11-30
US20020065320A1 (en) 2002-05-30
EA004047B1 (ru) 2003-12-25

Similar Documents

Publication Publication Date Title
BR0008631A (pt) Glicina betaìna para uso antitrombótico
Wu et al. Neutralization of heparin activity by neutrophil lactoferrin
Borges et al. Effects of aqueous extract of Casearia sylvestris (Flacourtiaceae) on actions of snake and bee venoms and on activity of phospholipases A2
BR9812228A (pt) Esponja de fibrina, processo para a preparação da mesma, uso de uma esponja de fibrina, e, kit.
CL2004000376A1 (es) Compuestos derivados de fenil propil amidas n-(aminoiminometil o aminometil) susttiuidas; compuestos intermediarios; composicion farmaceutica; y su uso para tratar un efecto patologico de la trombina, como trastornos tromboticos venosos o arteriales.
Carrijo et al. Biological properties of the venom from the scorpionfish (Scorpaena plumieri) and purification of a gelatinolytic protease
BR0207007A (pt) Composição farmcêutica, kit, usos de uma preparação e de uma composição, e, métodos para tratar de episódios de hemorragia em um paciente, para reduzir o tempo de coagulação em um paciente, para intensificar a hemostasia em um paciente para reduzir o número de administrações da proteìna do fator de coagulação necessário para deter a hemorragia e manter a hemostasia em um paciente, para reduzir a quantidade de proteìna do fator de coagulação administrada necessária para deter a hemorragia e manter a hemostasia em um paciente, para prolongar o tempo de lise do coágulo em um paciente, para aumentar a resistência do coágulo em paciente e para intensificar a formação de coágulo de fibrina em um paciente
BR0304660A (pt) Anticorpos direcionados a fator de tecido como anticoagulantes
DE60229406D1 (de) Verfahren zur behandlung oder verhinderung von vaskulärer entzündung mit sterol-absorbierungs- inhibitor(en)
BR0308663A (pt) Uso de inibidores de il-18 para o tratamento e/ou prevenção de doenças vasculares periféricas
BR9914735A (pt) Processo para tratamento de sépsia
Shu et al. Antimicrobial peptide cathelicidin-BF inhibits platelet aggregation by blocking protease-activated receptor 4
FI952593A0 (fi) Hyytymistä estävä aine
Cosmi et al. Additive thrombin inhibition by fast moving heparin and dermatan sulfate explains the anticoagulant effect of sulodexide, a natural mixture of glycosaminoglycans
Lu et al. Postoperative hemostasis and fibrinolysis in patients undergoing cardiopulmonary bypass with or without aprotinin therapy
Mahadeswaraswamy et al. Inhibition of local effects of Indian Daboia/Vipera russelli venom by the methanolic extract of grape (Vitis vinifera L.) seeds
Hasegawa Clinical assessment of warfarin therapy in patients with maintenance dialysis-clinical efficacy, risks and development of calciphylaxis
WO2000048625A3 (en) Inhibitors for use in hemostasis and immune function
ES2167364T3 (es) Inhibidores de trombina.
Cade et al. Early clinical experience of a new heparinoid, Org 10172, in prevention of deep venous thrombosis
Chaves et al. Intramuscular administration of antivenoms in experimental envenomation by Bothrops asper: comparison between Fab and IgG
Trento et al. Inhibitory properties of the anti-bothropic complex from Didelphis albiventris serum on toxic and pharmacological actions of metalloproteases and myotoxins from Bothrops asper venom
ATE498305T1 (de) Vermeidung und behandlung von krankheiten, die mit der blutgerinnung in zusammenhang stehen
Kumar et al. Malabarase, a serine protease with anticoagulant activity from Trimeresurus malabaricus venom
Oshima‐Franco et al. Neutralizing capacity of commercial bothropic antivenom against Bothrops jararacussu venom and bothropstoxin‐I

Legal Events

Date Code Title Description
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B15K Others concerning applications: alteration of classification

Free format text: ALTERADA DE INT.CL: A61K 31/205

Ipc: A61K 31/205 (2009.01), A61P 7/04 (2009.01), A61P 7

B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: INDEFIRO O PEDIDO DE ACORDO COM O(S) ARTIGO(S) 8O, 13 E 25 DA LPI.

B12B Appeal against refusal [chapter 12.2 patent gazette]